Results 101 to 110 of about 3,046 (215)

Mavacamten safety and efficacy in a heart transplant patient exhibiting obstructive hypertrophic cardiomyopathy phenotype

Hypertrophic cardiomyopathy is the most common inherited cardiac disease, exhibiting diverse phenotypes. Obstructive hypertrophic cardiomyopathy occurs in about two-thirds of cases and carries a worse prognosis.
Tajik, A Jamil, Misicka, Amanda, Abood, Zaid, Ashraf, Muddasir, Peters, Matthew, Galazka, Patrycja, Ghafoor, Asad, Jan, M Fuad, Jahangir, Arshad   +8 more
core   +1 more source

Anaphylactic Shock Probably due to a Cross‐Reaction Between Cefuroxime and Piperacillin—Presentation of a Fatal Case, Diagnostic Considerations, and Literature Review

Case Reports in Critical Care, Volume 2026, Issue 1, 2026.
Although beta‐lactam antibiotics are widely used in intensive care, rare but potentially fatal anaphylactic reactions can occur due to cross‐reactions between penicillins and cephalosporins. We report the case of a 68‐year‐old man who suffered perioperative cardiac arrest following the administration of cefuroxime.
August Fiegl, Arndt Hartmann, Christian Führling, Niklas Carbon, Roland C. E. Francis, Andreas Wehrfritz, Lipi Buch   +6 more
wiley   +1 more source

Recommendation of mavacamten posology by model‐based analyses in adults with obstructive hypertrophic cardiomyopathy

CPT: Pharmacometrics & Systems Pharmacology
Mavacamten is the first cardiac myosin inhibitor approved by the US Food and Drug Administration for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
Samira Merali, David H. Salinger, Maria Palmisano, Amy J. Sehnert, Neelima Thanneer, Hyunmoon Back, Julie D. Seroogy, Daniel D. Gretler, Amit Roy, Vidya Perera   +9 more
doaj   +1 more source

Temporal Patterns of Holter-Detected Arrhythmias in Hypertrophic Cardiomyopathy Patients Treated with Mavacamten

Biomedicines
Background: Hypertrophic cardiomyopathy (HCM) is a genetic cardiomyopathy marked by increased left ventricular wall thickness, leading in some cases to left ventricular outflow tract (LVOT) obstruction, heart failure, and arrhythmias.
Amro Badr, Kaitlin Roehl, Mustafa Suppah, Humam Abo Abdullah, Reza Arsanjani, Konstantinos C. Siontis, J. Geske, S. Ommen, J. Giudicessi, S. Alsidawi   +9 more
semanticscholar   +1 more source

Mavacamten for Left Ventricular Outflow Tract Obstruction After Successful Transcatheter Aortic Valve Implantation

JACC Case Reports
Hemodynamically significant left ventricular outflow tract obstruction is a rare complication of transcatheter aortic valve implantation (TAVI). This study presents an unusual case of a patient who, after a successful TAVI, developed and experienced ...
H. Jo, So-Min Lim, D. Pack, Tae Oh Kim, Sahmin Lee, B. Sun, Dae-Hee Kim, Jong-Min Song, D. Kang, Jae-Kwan Song   +9 more
semanticscholar   +1 more source

Mutation-specific Hypertrophic Cardiomyopathy and Mavacamten: a Mechano-energetic In Silico Study

, 2022
<p>Mavacamten is the first drug with proven efficacy for hypertrophic cardiomyopathy (HCM), the most prevalent genetic cardiac disorder. Our goal is to investigate the pathophysiology of the R403Q HCM mutation and the capability of Mavacamten to ...
Koivumäki, Jussi T., Hyttinen, Jari, Forouzandehmehr, Mohamadamin, Paci, Michelangelo, "Mohamadamin Forouzandehmehr, Jussi T. Koivumäki, Jari A. Hyttinen", Michelangelo Paci   +7 more
core   +1 more source

Phase 3 Open-Label Study Evaluating the Efficacy and Safety of Mavacamten in Japanese Adults With Obstructive Hypertrophic Cardiomyopathy　- The HORIZON-HCM Study.

Circulation Journal
BACKGROUND Mavacamten, a cardiac myosin inhibitor, significantly improved symptoms and cardiac function vs. placebo in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) in EXPLORER-HCM.
H. Kitaoka, Masaki Ieda, M. Ebato, K. Kozuma, Morimasa Takayama, Kaoru Tanno, Nobuyuki Komiyama, Yasushi Sakata, Yuichiro Maekawa, Y. Minami, A. Ogimoto, Tomohide Takaya, Satoshi Yasuda, E. Amiya, Yutaka Furukawa, Tetsuya Watanabe, D. Hiraya, H. Miyagoshi, Gen Kinoshita, A. Reedy, S. Hegde, Victoria Florea, Chisato Izumi   +22 more
semanticscholar   +1 more source

Biomechanical response of ultrathin slices of hypertrophic cardiomyopathy tissue to myosin modulator mavacamten [PDF]

Hypertrophic cardiomyopathy (HCM) is the most common inherited myocardial disorder of the heart, but effective treatment options remain limited. Mavacamten, a direct myosin modulator, has been presented as novel pharmacological therapy for HCM.
de Groot, Natasja M.S., Amesz, Jorik H., Langmuur, Sanne J.J.; id_orcid, Zhang, Lu, Taverne, Yannick J.H.J., de Jong, Peter L., Schinkel, Arend F.L., Manintveld, Olivier C.; id_orcid   +7 more
core   +1 more source

Precision Negative Inotropy: The Rise of Cardiac Myosin Inhibitors in HCM

Journal of Education, Health and Sport
Background: Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, marked by left-ventricular hypertrophy, dynamic outflow obstruction in many patients, diastolic dysfunction, and elevated risks of atrial fibrillation and heart ...
Katarzyna Skibicka, Tomasz Skibicki, Weronika Wesołowska, Robert Bujak   +3 more
doaj   +1 more source

Structure of mavacamten-free human cardiac thick filaments within the sarcomere by cryoelectron tomography

Proceedings of the National Academy of Sciences of the United States of America
Significance Cardiac muscle contains two filament types: thin filaments composed of actin and calcium regulatory proteins and thick filaments composed of myosin to produce force, titin to define the filament length, and myosin-binding protein C to ...
Liang Chen, Jun Liu, Hosna Rastegarpouyani, Paul M. L. Janssen, J. R. Pinto, Kenneth A. Taylor   +5 more
semanticscholar   +1 more source